Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016

Abstract

While the preterm neonate continues to benefit from improved perinatal care, the rate of preterm birth in the United States remains significant. An increasing body of scientific literature has demonstrated the benefits of maternal progesterone administration in reducing primary and recurrent preterm birth. Intramuscular hydroxyprogesterone caproate is indicated in singleton pregnancies in women with a prior spontaneous preterm birth, while vaginal progesterone demonstrates similar efficacy in prolonging pregnancy in women with asymptomatic cervical shortening in the midtrimester. Given these favorable benefits, the use of progesterone has been expanded to other clinical situations at risk for preterm birth with less rigorous scientific evidence. This review highlights the current evidence-based clinical applications of progesterone for prevention of preterm birth.

Keywords

preterm birth - recurrent preterm birth - progesterone - vaginal progesterone - cervical shortening

• References

• 1 Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2013. Natl Vital Stat Rep 2015; 64 (1) 1-65
• 2 Hauth JC, Gilstrap III LC, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983; 146 (2) 187-190
• 3 Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104 (1) 40-43
• 4 Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011; 28 (5) 377-381
• 5 Ruan X, Mueck AO. Systemic progesterone therapy—oral, vaginal, injections and even transdermal?. Maturitas 2014; 79 (3) 248-255
• 6 Sfakianaki AK, Norwitz ER. Mechanisms of progesterone action in inhibiting prematurity. J Matern Fetal Neonatal Med 2006; 19 (12) 763-772
• 7 Society for Maternal-Fetal Medicine Publications Committe. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206 (5) 376-386
• 8 Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62 (3) 485-490
• 9 Northen AT, Norman GS, Anderson K , et al; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007; 110 (4) 865-872
• 10 McNamara HC, Wood R, Chalmers J , et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS ONE 2015; 10 (4) e0122341
• 11 Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom (Kyoto) 2006; 46 (4) 194-198
• 12 Romero R, Nicolaides K, Conde-Agudelo A , et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012; 206 (2) 124.e1-124.e19
• 13 Lumara Health I. Makena prescribing information. Available at: http://www.makena.com/pdf/makena_pi.pdf . Accessed November 5, 2015
• 14 Meis PJ, Klebanoff M, Thom E , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348 (24) 2379-2385
• 15 How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?. Am J Obstet Gynecol 2007; 197 (3) 260.e1-260.e4
• 16 O'Brien JM, Adair CD, Lewis DF , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30 (5) 687-696
• 17 Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med 2014; 370 (3) 254-261
• 18 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206 (5) 376-386
• 19 Iams JD, Goldenberg RL, Meis PJ , et al; National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 1996; 334 (9) 567-572
• 20 Cahill AG, Odibo AO, Caughey AB , et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010; 202 (6) 548.e1-548.e8
• 21 Parry S, Simhan H, Elovitz M, Iams J. Universal maternal cervical length screening during the second trimester: pros and cons of a strategy to identify women at risk of spontaneous preterm delivery. Am J Obstet Gynecol 2012; 207 (2) 101-106
• 22 Pizzi LT, Seligman NS, Baxter JK, Jutkowitz E, Berghella V. Cost and cost effectiveness of vaginal progesterone gel in reducing preterm birth: an economic analysis of the PREGNANT trial. Pharmacoeconomics 2014; 32 (5) 467-478
• 23 Berghella V, Rafael TJ, Szychowski JM, Rust OA, Owen J. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011; 117 (3) 663-671
• 24 Szychowski JM, Berghella V, Owen J , et al; Vaginal Ultrasound Trial Consortium. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate. J Matern Fetal Neonatal Med 2012; 25 (12) 2686-2689
• 25 Conde-Agudelo A, Romero R, Nicolaides K , et al. Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol 2013; 208 (1) 42.e1-42.e18
• 26 Alfirevic Z, Owen J, Carreras Moratonas E, Sharp AN, Szychowski JM, Goya M. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. Ultrasound Obstet Gynecol 2013; 41 (2) 146-151
• 27 Rozenberg P, Chauveaud A, Deruelle P , et al; Groupe De Recherche En Obstétrique et Gynécologie. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2012; 206 (3) 206.e1-206.e9
• 28 Saccone G, Suhag A, Berghella V. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015; 213 (1) 16-22
• 29 Eke AC, Chalaan T, Shukr G, Eleje GU, Okafor CI. A systematic review and meta-analysis of progestogen use for maintenance tocolysis after preterm labor in women with intact membranes. Int J Gynaecol Obstet 2015; 132 (1) 11-16 . doi:10.1016/j.ijgo.2015.06.058
• 30 Rouse DJ, Caritis SN, Peaceman AM , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007; 357 (5) 454-461
• 31 Combs CA, Garite T, Maurel K, Das A, Porto M ; Obstetrix Collaborative Research Network. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2011; 204 (3) 221.e1-221.e8
• 32 Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A ; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280
• 33 Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A ; PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 2011; 38 (3) 281-287
• 34 Reddy U. A trial of pessary and progesterone for preterm prevention in twin gestation with a short cervix (PROSPECT). Available at: ClinicalTrials.gov. Published 2015